917796

NanoFabTx^™ PEG-PLGA drug formulation screening kit

for synthesis of PEGylated nanoparticles

• Synonym(e): NanoFabTx reagent kit, PEG-PLGA nanoparticles
• UNSPSC-Code: 12161503
• NACRES: NA.23

Eigenschaften

• Beschreibung: Drug loading screening kit, for synthesis of PEGylated PLGA nanoparticles; Kit components : ; PEGPLGA-50L(912808-500mg); PEGPLGA-75L(913049-500mg); PEGPLGA-50H (915955-500mg); PEGPLGA-75H (915718-500mg); Stabilizer-Nano (907766-5g)
• Qualitätsniveau: 100
• Anwendung(en): advanced drug delivery
• Lagertemp.: 2-8°C

Beschreibung

Allgemeine Beschreibung

NanoFabTx^™ PEG-PLGA drug loading screening kit is a ready-to-use nanoformulation kit for the synthesis of PEGylated PLGA nanoparticles 50 nm to 350 nm in size. This kit provides properly selected PEGylated PLGAs, stabilizer, and formulation protocols for synthesis by nanoprecipitation and microfluidic methods. Four different PEGylated PLGAs are included in this kit, allowing rapid screening of optimal materials for enhancing drug loading. Protocols for two different particle synthesis methods are included.

• A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
• A Microfluidics protocol using commercial platforms or syringe pumps.

The microfluidics protocol uses NanoFabTx^™ device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Anwendung

NanoFabTx^™ nanoformulation reagent kits enable users to encapsulate a wide variety of therapeutic drug molecules in PEGylated PLGA nanocarriers for targeted or sustained drug delivery without the need for lengthy trial-and-error optimization. PEGylated PLGAs are well suited towards applications involving sustained release because PEGylation has been shown to improve the circulation half-life of polymeric nanocarriers by altering the solubility and shielding the nanocarrier from enzymes and antibodies that may induce degradation, secretion, and clearance. Because poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable polymer approved by the FDA for biomedical and pharmaceutical applications, PLGA-based nanoparticles synthesized with the NanoFabTx^™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

Leistungsmerkmale und Vorteile

• Requires minimal laboratory setup
• Optimized protocols with step-by-step instructions for either nanoprecipitation or microfluidics-based synthesis
• Yields specifically sized, low polydispersity biodegradable, PEGylated PLGA nanoparticles from 50 nm to 350 nm in size
• Maximizes the encapsulation of hydrophobic drugs
• Four different PEGylated PLGAs are included

Rechtliche Hinweise

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 10 - Combustible liquids